Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXICURE, INC.XCUR · Entity 8068 | Director | June 13, 2022 | June 15, 2022 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | July 22, 2025 | July 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXICURE, INC.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2032-06-12 | Direct | 50,000 |
Reported balance
After 2022-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
SPRUCE BIOSCIENCES, INC.
Report date July 22, 2025 · Filed July 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2035-07-21 | Direct | 30,000 |
Reported balance
After 2025-07-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2025 Filed Jul 24, 2025 23:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020261 · form4-07242025_110724.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:26 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-014491 · form4-05242024_080524.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:14 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-23-035563 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:38 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032657 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:17 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001209191-22-036942 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-034176 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-22-032507 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 19, 2022 Filed May 19, 2022 20:50 UTC | EXICURE, INC. XCUR · Entity 8068 | PurchaseCommon Stock | 1,472,126 | $0.19 | $285,150.81 |
DisclosureSEC source: 0001209191-22-030549 · doc4.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,449,126 F1 · ownership.nature: The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, (together with Abingworth Bioventures VII GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures VII GP LP. Abingworth VII (acting by its general partner Abingworth Bioventures VII GP LP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth VII. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth VII. F2 · ownership.nature: Each of Abingworth VII, Abingworth LLP, the General Partners, the Reporting Person and each member of the investment committee disclaims beneficial ownership of the common stock held by Abingworth VII, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 21:34 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 111,736 | $8.50 | $949,756.00 |
DisclosureSEC source: 0001209191-21-046803 · doc4.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 2,073,957 F1 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F2 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 13:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 20,710 | $9.28 | $192,244.72 |
DisclosureSEC source: 0000905718-21-000834 · reneo_fm4jun232021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,962,221 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.23 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F3 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 12:33 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 14,615 | $8.72 | $127,486.65 |
DisclosureSEC source: 0000905718-21-000816 · reneo_fm4jun212021.xml · nonDerivative · entry 2 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,941,511 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.55 to $9.30 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F3 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:33 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 32,659 | $9.03 | $294,927.10 |
DisclosureSEC source: 0000905718-21-000816 · reneo_fm4jun212021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,926,896 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.55 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F3 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 13:00 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 16,605 | $9.50 | $157,709.31 |
DisclosureSEC source: 0000905718-21-000770 · reneo_fm4jun82021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,894,237 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.44 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F3 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 12:53 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 257 | $9.42 | $2,422.02 |
DisclosureSEC source: 0000905718-21-000760 · reneo_fm4jun32021.xml · nonDerivative · entry 2 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,877,632 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F4 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 12:53 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 12,100 | $9.25 | $111,943.15 |
DisclosureSEC source: 0000905718-21-000760 · reneo_fm4jun32021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,877,375 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F4 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:17 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-21-038324 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 14:37 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 14 | $9.50 | $133.00 |
DisclosureSEC source: 0000905718-21-000744 · reneo_fm4may282021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,865,275 F1 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F2 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 1,120 | $9.26 | $10,369.30 |
DisclosureSEC source: 0000905718-21-000738 · reneo_fm4may262021.xml · nonDerivative · entry 2 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,865,261 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.115 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F4 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:10 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 5,915 | $9.38 | $55,495.12 |
DisclosureSEC source: 0000905718-21-000738 · reneo_fm4may262021.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,864,141 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.46 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. F4 · ownership.nature: Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 20, 2021 Filed May 22, 2021 01:08 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001209191-21-035149 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:15 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionSeries B Preferred Stock · Derivative | 7,420,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026823 · doc4.xml · derivative · entry 3 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 0 Underlying: Common Stock · 1,658,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: See Exhibit 99.1 Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:15 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-21-026823 · doc4.xml · nonDerivative · entry 2 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,858,226 F3 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: See Exhibit 99.1 Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 20:15 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | ConversionCommon Stock | 1,658,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-026823 · doc4.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Abingworth Bioventures 8 LP Disclosed balance after: 1,658,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date. F2 · ownership.nature: See Exhibit 99.1 Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 19:09 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026336 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-04-07 F1 · derivative.exercise_date: The shares subject to the option vest on April 8, 2022. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:24 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | ConversionSeries B Preferred Stock · Derivative | 10,416,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055016 · doc4.xml · derivative · entry 3 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,592,518 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date. F2 · ownership.nature: The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP ("Abingworth GP VII"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP. F3 · ownership.nature: The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII. Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:24 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-20-055016 · doc4.xml · nonDerivative · entry 2 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,792,518 F4 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP ("Abingworth GP VII"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP. F3 · ownership.nature: The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII. Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 16:24 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | ConversionCommon Stock | 1,592,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055016 · doc4.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,592,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020) The shares have no expiration date. F2 · ownership.nature: The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP ("Abingworth GP VII"), serves as the general partners of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP VII) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The Reporting Person is a Partner of ALLP. F3 · ownership.nature: The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth VII which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the securities held by Abingworth VII. Each of Abingworth VII, Abingworth GP, Abingworth GP VII, and each member of the investment committee disclaims beneficial ownership of the shares held by Abingworth VII. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 20:27 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 21,693 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001209191-20-035256 · doc4.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,693 Underlying: Common Stock · 21,693 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:05 UTC | EXICURE, INC. XCUR · Entity 8068 | PurchaseCommon Stock $0.0001 par value | 727,000 | $2.75 | $1,999,250.00 |
DisclosureSEC source: 0000905718-19-000989 · exicure_fm4dec192019.xml · nonDerivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,977,000 F1 · ownership.nature: The shares are held by Abingworth Bioventures VII LP ("Abingworth VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VII. ALLP holds the reported securities indirectly through Abingworth VII. The reporting person is an employee of ALLP. F2 · ownership.nature: The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 20:18 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock option (right to buy) · Derivative | 43,386 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000905718-19-000661 · exicure_fm4aug22019.xml · derivative · entry 1 Muralidhar Bali · CIK 0001784138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,386 Underlying: Common Stock · 43,386 shares Expires 2029-08-01 F1 · derivative.exercise_date: This option vests in 36 substantially equal monthly installments from August 2, 2019, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.